Evaluation of the sensitivities of six triple-negative breast cancer (TNBC) cell lines to 23 different PI3K/AKT/mTOR inhibitors or to a MEK inhibitor (trametinib). Dataset 2 of 2: GR metrics. - Dataset - HMS LINCS Database

Evaluation of the sensitivities of six triple-negative breast cancer (TNBC) cell lines to 23 different PI3K/AKT/mTOR inhibitors or to a MEK inhibitor (trametinib). Dataset 2 of 2: GR metrics. - Dataset (ID:20365)

Download: Excel (XLSX), Comma-separated (CSV)

Filter results: >>>>

|<
<<
Previous
Page 3 of 18
Next
>>
>
51 to 75 of 432 records
per page:

Cell line	Drug name	Experimental replicate	Timepoint	Curve type (GR values)	Curve type (relative cell counts)	Experiment name	Number of concentrations	Cell doublings (DMSO control)	GR50	GRmax	GR_AOC	GEC50	GRinf	Hill slope (GR values)	R-squared sigmoid fit (GR values)	P-value sigmoid fit (GR values)	R-squared flat fit (GR values)	IC50	Emax	AUC	EC50	Einf	Hill slope (relative cell counts)	R-squared sigmoid fit (relative cell counts)	P-value sigmoid fit (relative cell counts)	R-squared flat fit (relative cell counts)
BT-20	XL147	3	72	flat	flat	BT20 pilaralisib 0 3 72	8	2.647	Inf	0.755	0.102	0.0	0.755	0.01	0.0679	0.81	0.885	Inf	0.708	0.871	0.0	0.708	0.01	0.0505	0.856	0.857
BT-20	Sirolimus	1	72	flat	flat	BT20 rapamycin 0 1 72	8	2.100	Inf	0.568	0.431	0.0	0.568	0.01	-9.89	1.0	0.568	Inf	0.6	0.601	0.0	0.6	0.01	-13.0	1.0	0.6
BT-20	Sirolimus	2	72	flat	flat	BT20 rapamycin 0 2 72	8	1.952	Inf	0.421	0.579	0.0	0.421	0.01	NA	NA	0.421	Inf	0.513	0.513	0.0	0.513	0.01	NA	NA	0.513
BT-20	Sirolimus	3	72	flat	flat	BT20 rapamycin 0 3 72	8	2.661	Inf	0.54	0.46	0.0	0.54	0.01	NA	NA	0.54	Inf	0.499	0.499	0.0	0.499	0.01	NA	NA	0.499
BT-20	TGX221	1	72	flat	flat	BT20 TGX-221 0 1 72	8	1.988	Inf	1.02	-0.00357	0.0	1.02	0.01	-0.00762	1.0	1.0	Inf	1.02	1.0	0.0	1.02	0.01	-0.00881	1.0	1.0
BT-20	TGX221	2	72	flat	flat	BT20 TGX-221 0 2 72	8	1.656	Inf	1.0	0.0477	0.0	1.0	0.01	-0.101	1.0	0.946	Inf	1.0	0.961	0.0	1.0	0.01	-0.101	1.0	0.956
BT-20	TGX221	3	72	flat	flat	BT20 TGX-221 0 3 72	8	2.469	Inf	1.01	0.0147	0.0	1.01	0.01	-0.0563	1.0	0.982	Inf	1.01	0.983	0.0	1.01	0.01	-0.0552	1.0	0.979
BT-20	Torin1	1	72	sigmoid	sigmoid	BT20 Torin1 0 1 72	8	2.022	0.0383	-0.105	0.566	0.0658	-0.179	0.565	0.991	7.45e-07	NA	0.0591	0.197	0.536	0.0286	0.182	0.624	0.994	2.54e-07	NA
BT-20	Torin1	2	72	sigmoid	sigmoid	BT20 Torin1 0 2 72	8	1.793	0.00766	-0.152	0.806	0.00992	-0.146	0.986	0.986	2.59e-06	NA	0.0131	0.215	0.421	0.00727	0.212	0.936	0.988	1.92e-06	NA
BT-20	Torin1	3	72	sigmoid	sigmoid	BT20 Torin1 0 3 72	8	2.569	0.0237	0.0343	0.572	0.0199	0.0736	0.899	0.993	2.77e-07	NA	0.0208	0.184	0.46	0.0119	0.204	0.944	0.997	2.51e-08	NA
BT-20	Torin2	1	72	sigmoid	sigmoid	BT20 Torin2 0 1 72	8	2.018	0.0185	-0.739	0.803	0.158	-1.0	0.511	0.986	2.9e-06	NA	0.0245	0.0164	0.415	0.0245	0.0	0.616	0.99	1.06e-06	NA
BT-20	Torin2	2	72	sigmoid	sigmoid	BT20 Torin2 0 2 72	8	1.733	0.00315	-0.761	0.992	0.0484	-0.95	0.389	0.949	0.000131	NA	0.00804	0.0252	0.336	0.00642	0.0613	0.583	0.974	1.77e-05	NA
BT-20	Torin2	3	72	sigmoid	sigmoid	BT20 Torin2 0 3 72	8	2.458	0.019	-0.64	0.751	0.234	-1.0	0.438	0.959	6.92e-05	NA	0.0147	0.0148	0.379	0.0123	0.0598	0.727	0.977	1.28e-05	NA
BT-20	Trametinib	1	72	sigmoid	sigmoid	BT20 trametinib 0 1 72	8	2.016	14.3	0.54	0.225	0.135	0.458	0.534	0.989	1.3e-06	NA	Inf	0.59	0.791	0.0955	0.534	0.545	0.989	1.43e-06	NA
BT-20	Trametinib	2	72	sigmoid	sigmoid	BT20 trametinib 0 2 72	8	1.723	0.761	0.303	0.289	11.1	-0.768	0.347	0.965	4.13e-05	NA	2.56	0.478	0.77	2.56	0.0	0.362	0.957	8.16e-05	NA
BT-20	Trametinib	3	72	sigmoid	sigmoid	BT20 trametinib 0 3 72	8	2.539	Inf	0.64	0.208	0.104	0.541	0.392	0.967	3.69e-05	NA	Inf	0.604	0.761	0.0656	0.513	0.391	0.964	4.56e-05	NA
BT-20	WYE-125132	1	72	sigmoid	sigmoid	BT20 WYE-132 0 1 72	8	2.067	0.0893	0.289	0.402	0.0435	0.256	1.0	0.987	2.28e-06	NA	0.154	0.403	0.647	0.0353	0.375	0.941	0.985	3.56e-06	NA
BT-20	WYE-125132	2	72	sigmoid	sigmoid	BT20 WYE-132 0 2 72	8	2.053	0.012	0.142	0.633	0.00936	0.072	0.621	0.909	0.000752	NA	0.0232	0.316	0.475	0.00613	0.255	0.536	0.894	0.00119	NA
BT-20	WYE-125132	3	72	sigmoid	sigmoid	BT20 WYE-132 0 3 72	8	2.654	0.0504	0.282	0.465	0.0254	0.236	0.929	0.922	0.000468	NA	0.048	0.307	0.526	0.0182	0.246	0.698	0.918	0.000553	NA
BT-20	ZSTK474	1	72	sigmoid	sigmoid	BT20 ZSTK474 0 1 72	8	1.940	0.788	0.0217	0.122	0.819	-0.0395	1.99	0.957	7.76e-05	NA	0.942	0.272	0.913	0.677	0.249	2.09	0.934	0.000293	NA
BT-20	ZSTK474	2	72	sigmoid	sigmoid	BT20 ZSTK474 0 2 72	8	1.787	0.286	-0.19	0.347	0.373	-0.234	1.46	0.992	4.53e-07	NA	0.391	0.199	0.743	0.29	0.184	1.55	0.988	1.84e-06	NA
BT-20	ZSTK474	3	72	sigmoid	sigmoid	BT20 ZSTK474 0 3 72	8	2.609	0.457	-0.00222	0.296	0.783	-0.31	0.895	0.982	5.76e-06	NA	0.422	0.163	0.702	0.422	0.0	0.82	0.971	2.52e-05	NA
BT-549	Alpelisib	1	72	flat	flat	BT549 alpelisib 0 1 72	8	1.822	Inf	0.747	0.0781	0.0	0.747	0.01	0.439	0.176	0.914	Inf	0.782	0.931	0.0	0.782	0.01	0.415	0.2	0.925
BT-549	Alpelisib	2	72	sigmoid	sigmoid	BT549 alpelisib 0 2 72	8	1.927	Inf	0.832	0.0409	4.24	0.663	0.548	0.706	0.0254	NA	Inf	0.844	0.962	4.26	0.686	0.542	0.696	0.0282	NA
BT-549	Alpelisib	3	72	flat	flat	BT549 alpelisib 0 3 72	8	1.743	Inf	0.817	0.068	0.0	0.817	0.01	-0.0192	1.0	0.915	Inf	0.846	0.942	0.0	0.846	0.01	-0.0162	1.0	0.928

|<
<<
Previous
Page 3 of 18
Next
>>
>
51 to 75 of 432 records
per page:

HMS LINCS Project

Evaluation of the sensitivities of six triple-negative breast cancer (TNBC) cell lines to 23 different PI3K/AKT/mTOR inhibitors or to a MEK inhibitor (trametinib). Dataset 2 of 2: GR metrics. - Dataset (ID:20365)